Bruce G. Robinson

Research interests

Publications

• Phase 3 Trial of Selpercatinib in Advanced RET -Mutant Medullary Thyroid Cancer

  New England Journal of Medicine · 2023 · https://doi.org/10.1056/nejmoa2309719

• RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies

  Journal of Thoracic Oncology · 2020 · https://doi.org/10.1016/j.jtho.2020.01.006

• 15 YEARS OF PARAGANGLIOMA: Clinical manifestations of paraganglioma syndromes types 1–5

  Endocrine Related Cancer · 2015 · https://doi.org/10.1530/erc-15-0268

• Succinate Dehydrogenase (SDH)-deficient Renal Carcinoma

  The American Journal of Surgical Pathology · 2014 · https://doi.org/10.1097/pas.0000000000000292

• Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial

  Journal of Clinical Oncology · 2011 · https://doi.org/10.1200/jco.2011.35.5040

• Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes

  Human Pathology · 2010 · https://doi.org/10.1016/j.humpath.2009.12.005

• Immunohistochemistry for SDHB Divides Gastrointestinal Stromal Tumors (GISTs) into 2 Distinct Types

  The American Journal of Surgical Pathology · 2010 · https://doi.org/10.1097/pas.0b013e3181d6150d

• Clinical Predictors for Germline Mutations in Head and Neck Paraganglioma Patients: Cost Reduction Strategy in Genetic Diagnostic Process as Fall-Out

  Cancer Research · 2009 · https://doi.org/10.1158/0008-5472.can-08-4057

• miR-195 and miR-483-5p Identified as Predictors of Poor Prognosis in Adrenocortical Cancer

  Clinical Cancer Research · 2009 · https://doi.org/10.1158/1078-0432.ccr-09-1587

• Clinical Presentation and Penetrance of Pheochromocytoma/Paraganglioma Syndromes

  The Journal of Clinical Endocrinology & Metabolism · 2006 · https://doi.org/10.1210/jc.2005-1862

Current projects

No projects listed.